Clinical evaluations of montelukast sodium in the treatment of children with asthma
OBJECTIVE To evaluate the comprehensive clinical value of domestic and imported montelukast sodium(MS)in the treatment of children with asthma.METHODS Six dimensions of safety,effectiveness,economy,suitability,accessibility and innovation,expert consultation and literature survey were employed for determining the clinical comprehensive evaluation index system.Delphi method and analytic hierarchy process were utilized for screening the index system and determine the weights of all indices.Evidence collection proceeded through literature researches,real world researches and questionnaire surveying.Experts were invited to score MS according to evidence sets.Total score of clinical comprehensive evaluation of two drugs was calculated by the weights of indices.RESULTS A comprehensive clinical evaluation index system of MS was established,including 6 primary indices(safety,effectiveness,suitability,accessibility,economy & innovation),14 secondary indices and 32 tertiary indices.Total score of MS centrally purchased domestically was 8.12 points and total score of imported original drug was 8.03 points.The scores of safety,effectiveness and innovation of imported original research drugs were slightly higher than those of pooled drugs.And the scores of economy,accessibility and suitability of pooled drugs were slightly higher than those of imported original research drugs.CONCLUSION The comprehensive clinical value of MS centrally purchased domestically for treating pediatric asthma is superior to that of imported original drugs.
NETL
